An IPR warning shot for pharma that could resonate far and wide
Earlier this week US hedge fund investor Kyle Bass got the wires buzzing when he reportedly outlined his plans to wage an inter partes review (IPR) war on big pharma at the USPTO’s Patent Trial and Appeal Board (PTAB). According to Bass,…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now